[Divergent Earnings Reports from Blood Testing Companies: Natera's Loss Exceeds Expectations] According to Investor’s Business Daily, on November 6th, blood testing companies Natera and Guardant Health released their third-quarter earnings reports, with both companies raising their full-year revenue guidance. This followed weak sales of their competitor Grail's cancer testing product, Galleri, which disappointed investors. Natera reported a loss of $0.42 per share, higher than the market expectation of $0.29; revenue was $794 million, higher than the expected $708 million. Guardant Health reported a loss of $0.29 per share, lower than the expected $0.31; revenue was $361 million, higher than the expected $351 million. The report also stated that Veracyte, a cancer tissue testing company, experienced weak prostate cancer testing; 10x Genomics, a laboratory research tools company, reported a third-quarter loss of $0.15 per share, with revenue of $150.7 million, both better than market expectations.